PremiumCompany AnnouncementsOutlook Therapeutics Announces New Stock and Warrant Offering Outlook Therapeutics 9.3M share Spot Secondary priced at $1.40 Outlook Therapeutics Reports Improved Financials Amid Challenges PremiumCompany AnnouncementsOutlook Therapeutics Approves Retention Incentive for CFO Outlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010 Outlook Therapeutics files to sell 21.72M shares of common stock for holders PremiumThe FlyOutlook Therapeutics price target lowered to $10 from $12 at Guggenheim Positive Outlook on Outlook Therapeutics: Buy Rating Supported by Strategic Launches and Market Opportunities for Lytenava Outlook Therapeutics price target lowered to $3 from $30 at H.C. Wainwright 
